Needle-free influenza vaccination. (Q30394326)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883966%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Needle-free influenza vaccination (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883966%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883966%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883966%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Anke Huckriede

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883966%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Jean-Pierre Amorij

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883966%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Jan C Wilschut

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883966%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

1 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883966%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883966%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883966%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883966%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

699-711

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883966%20AND%20SRC:MED&resulttype=core&format=json

Needle-free vaccine delivery

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Immunization without needles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Needle-free vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Vaccine delivery--current trends and future

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Novel approaches to vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Antigen delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Intranasal Influenza Vaccine in a Working Population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Development of stable influenza vaccine powder formulations: challenges and possibilities

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Innate signaling and regulation of Dendritic cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Molecular and cellular signatures of human vaccine adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Towards an understanding of the adjuvant action of aluminium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Recent advances in antigen processing and presentation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

New insights into the early molecular events underlying B cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Mucosal vaccines: the promise and the challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Nasal delivery systems and their effect on deposition and absorption

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Enteric immunization of mice against influenza with recombinant vaccinia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Towards an oral influenza vaccine: comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Trends in the technology-driven development of new inhalation devices

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Pulsatile drug delivery to ileo-colonic segments by structured incorporation of disintegrants in pH-responsive polymer coatings

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Adjuvants: progress, regress and pandemic preparedness

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

The virosome concept for influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Intranasal immunization with influenza virus and Korean mistletoe lectin C (KML-C) induces heterosubtypic immunity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Protective and cross-protective mucosal immunization of mice by influenza virus type A with bacterial adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Immunostimulating complexes (ISCOMs) for nasal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Local immune responses following nasal delivery of an adjuvanted influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Effective nasal influenza vaccine delivery using chitosan

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Chitosan as a novel nasal delivery system for vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Sublingual vaccination with influenza virus protects mice against lethal viral infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Transcutaneous immunization with inactivated influenza virus induces protective immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Epidermal powder immunization of mice and monkeys with an influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

New adjuvants: EU regulatory developments

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Search for Herpesviruses in cerebrospinal fluid of facial palsy patients by PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Animal models in influenza vaccine testing.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Animal models for the preclinical evaluation of candidate influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

T cell responses are better correlates of vaccine protection in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Preservation of influenza virosome structure and function during freeze-drying and storage

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Intranasal, cold-adapted, live, attenuated influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

A non-living nasal influenza vaccine can induce major humoral and cellular immune responses in humans without the need for adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Noninvasive delivery technologies: respiratory delivery of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Anthrax vaccine powder formulations for nasal mucosal delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Formulation of a dry powder influenza vaccine for nasal delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Evaluation of the clearance characteristics of bioadhesive systems in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

In vivo evaluation of nicotine lyophilised nasal insert in sheep

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Drug delivery to the nasal cavity: in vitro and in vivo assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Devices for aerosol delivery to treat sinusitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Novel strategies of aerosolic pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Mucosal immunity and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Anatomical location determines the distribution and function of dendritic cells and other APCs in the respiratory tract

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Pulmonary dendritic cells in local immunity to inert and pathogenic antigens in the respiratory tract

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Mucosal immunity: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Influenza Antibody in Human Respiratory Secretions after Subcutaneous or Respiratory Immunization with Inactivated Virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

The efficacy of the A2/Aichi/68 strain in inhaled influenza immunisation against the A/England/42/72 variant.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

A review of the development of Respimat Soft Mist Inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Pulmonary vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Safety evaluation of pulmonary influenza vaccination in healthy and "asthmatic" mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Delivery of bioactive peptides and proteins across oral (buccal) mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Overview and research agenda arising from the 5th World Workshop on Oral Health and Disease in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Modulation of gamma delta T cells in mouse buccal epithelium following antigen priming

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

M cells at locations outside the gut.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Human salivary immunoglobulin and antigen-specific antibody activity after tonsillectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Noninjection routes for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Sublingual immunization induces broad-based systemic and mucosal immune responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Human immune responses to influenza virus vaccines administered by systemic or mucosal routes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Immunization against influenza in humans using an oral enteric-coated killed virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Antibody in tears, saliva and nasal secretions following oral immunization of humans with inactivated influenza virus vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Time-controlled oral delivery systems for colon targeting

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Topical vaccination: the skin as a unique portal to adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Morphological and quantitative analyses of normal epidermal Langerhans cells using confocal scanning laser microscopy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Serum antibody responses after intradermal vaccination against influenza

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Dose sparing with intradermal injection of influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Immunogenicity and safety of intradermal influenza vaccination in healthy older adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Antibody responses after dose-sparing intradermal influenza vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Efficacy of intradermal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Microneedles for transdermal drug delivery: a minireview

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Needle-free liquid jet injections: mechanisms and applications

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Current status and future prospects of needle-free liquid jet injectors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

A needle-free approach for topical immunization: antigen delivery via vesicular carrier system(s).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Transcutaneous immunization and immunostimulant strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Epidermal powder immunization against influenza

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Transdermal influenza immunization with vaccine-coated microneedle arrays

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Coating formulations for microneedles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

Dissolving microneedles for transdermal drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970157-2

7 January 2021

10.1016/S1473-3099(10)70157-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883966%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20883966%20AND%20SRC:MED&resulttype=core&format=json